Clinical Differentiating Factors for Pleural-Based Masses in a 6-Year-Old Child
In a 6-year-old child with a large right-sided pleural-based heterogeneous mass causing rib erosion, lung collapse, and mediastinal shift, the following table differentiates the key clinical features:
| Feature | Pleuropulmonary Blastoma | Ewing Sarcoma of Rib | Pleural Tuberculoma | Primary Pulmonary Synovial Sarcoma |
|---|---|---|---|---|
| Age of Presentation | 0-6 years (peak incidence) [1,2] | Median 14 years; 90% <20 years [3,4] | Any age; endemic areas | Young adults; extremely rare in children [5,6] |
| Genetic Marker | DICER1 germline mutation (pathognomonic) [1,2,7] | t(11;22)(q24;q12) translocation; CD99+ [3,8] | None | t(X;18)(p11;q11) translocation (SYT-SSX fusion) [6,9] |
| Imaging Characteristics | Heterogeneous mass; cystic, mixed, or solid components; right-sided predominance; NO chest wall invasion; pleural fluid common [10,2] | Mottled bone appearance; "onion skin" periosteal reaction; large soft tissue component; rib-based [3,8] | Calcifications common; pleural thickening; may have associated lymphadenopathy | Well-circumscribed; heterogeneous enhancement; multilocular fluid-filled components; peripheral rim enhancement [6] |
| Constitutional Symptoms | Respiratory distress; fever possible [11] | Fever, weight loss, fatigue common (unlike other bone sarcomas) [3,8] | Fever, night sweats, weight loss; chronic symptoms | Cough, chest pain, dyspnea [5,6] |
| Laboratory Findings | Normal or nonspecific | Elevated LDH, leukocytosis [3,8] | Positive tuberculin skin test/IGRA; elevated ESR | Nonspecific |
| Primary Site | Lung parenchyma and pleural surfaces [2] | Rib/chest wall bone origin [3] | Pleura (secondary to pulmonary TB) | Pleura or lung (no bone involvement) [6] |
| Bone Involvement | Absent (key differentiator) [10] | Rib erosion/destruction with periosteal reaction [3] | Rare; adjacent bone may show reactive changes | Absent (except chest wall primary) [6] |
| Pleural Effusion | Common [10,2] | Possible but less characteristic | Common; often exudative | Common [6] |
| Metastatic Pattern | Lungs, brain (rare but reported) [10] | Lungs, bones, bone marrow [3,8] | Miliary spread; other organs | Brain metastases documented (extremely rare) [5] |
| Family History | Positive oncological family history suggestive (DICER1 syndrome) [1,10] | Negative | TB exposure history | Negative |
| Histopathology | Embryonal cancer; primitive mesenchymal cells; requires DICER1 testing [2,7] | Small round blue cells; CD99 strongly positive [3,8] | Granulomatous inflammation; caseous necrosis; AFB staining | Biphasic pattern (epithelial and spindle cells); SYT-SSX fusion [6,9] |
Critical Diagnostic Pitfalls
The most important discriminator in this 6-year-old is the presence or absence of rib/bone involvement and DICER1 mutation status. 10, 2
Key Decision Points:
If NO bone invasion is present: Strongly favor pleuropulmonary blastoma over Ewing sarcoma. PPB characteristically does NOT invade chest wall despite large size 10, 2
If "onion skin" periosteal reaction is visible: This is pathognomonic for Ewing sarcoma 3, 8
If age <6 years with right-sided mass: PPB is statistically most likely; occurs in 0-6 year age group 1, 2
If constitutional symptoms + elevated LDH: More consistent with Ewing sarcoma than other differentials 3, 8
If TB endemic area + chronic symptoms: Consider tuberculoma, but obtain tissue diagnosis as malignancy cannot be excluded radiologically
If heterogeneous mass with multilocular cystic components: PPB type II (mixed) is most likely 2, 7
Mandatory Workup to Differentiate:
- Biopsy with molecular testing: DICER1 mutation analysis, EWSR1 translocation testing, SYT-SSX fusion testing 1, 8, 7
- Bone marrow biopsy: Required for Ewing sarcoma staging 3, 8
- TB testing: Tuberculin skin test/IGRA if endemic area or exposure history
- Family history: Detailed oncological family history for DICER1 syndrome 1, 10
Primary pulmonary synovial sarcoma is exceedingly rare in this age group and should be a diagnosis of exclusion after molecular confirmation. 5, 6